

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/023146

International filing date: 19 July 2004 (19.07.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/488,525  
Filing date: 18 July 2003 (18.07.2003)

Date of receipt at the International Bureau: 06 September 2004 (06.09.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME


UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

*August 29, 2004*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/488,525**  
**FILING DATE: *July 18, 2003***  
**RELATED PCT APPLICATION NUMBER: *PCT/US04/23146***

Certified by



Jon W Dudas

Acting Under Secretary of Commerce  
for Intellectual Property  
and Acting Director of the U.S.  
Patent and Trademark Office



16562 U.S. PTO  
07/18/03

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EU359085097US

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Ronald P. W. Robert S.		Lesser Webber		Baltimore, MD Ellicott City, MD	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
Method for Treating Nausea and Vomiting in Pregnancy					
Direct all correspondence to:					
<input type="checkbox"/> Customer Number		CORRESPONDENCE ADDRESS			
OR		Type Customer Number here		Place Customer Number Bar Code Label here	
<input checked="" type="checkbox"/> Firm or Individual Name		Johns Hopkins University			
Address		100 N. Charles Street			
Address		5th Floor			
City		Baltimore		State	MD
Country		USA	Telephone	410-516-8300	Fax 410-516-5113
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification		Number of Pages		9	
<input checked="" type="checkbox"/> Drawing(s)		Number of Sheets		1	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		<input type="checkbox"/> CD(s), Number			
		<input type="checkbox"/> Other (specify)			
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:					
<input checked="" type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.				\$80.00	
The invention was made by an agency of the United States Government or under a contract with an agency of the					
United States Government.					
<input type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:					

Respectfully submitted,

SIGNATURE

*Heather Bakalyar*

Date

7.18.03

TYPED or PRINTED NAME

Heather Bakalyar, Ph.D.

REGISTRATION NO.

(if appropriate)

Docket Number:

45,282

4247

TELEPHONE 410-516-8300

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

**CERTIFICATE OF EXPRESS MAILING**

**EXPRESS MAILING LABEL NO.**

EU 359085097 US

---

I hereby certify that this correspondence (along with any papers referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail, Post Office to Addressee with sufficient postage in a **Flat Rate** envelope addressed to MS Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below:

07-18-03

DATE of Signature  
And of Mail Deposit

Cheryl Alexroad

Signature

4247

## Method for Treating Nausea and Vomiting

Inventors: Ronald P. Lesser, M.D.; 709 Stevenson Lane; Baltimore, Maryland 21286-7905  
W.R.S. Webber, Ph.D.; 5471 Autumn Field Ct.; Ellicott City, Maryland 21043-7097  
Both of MD (US)

Assignee: The Johns Hopkins University, Baltimore, Maryland (US)

## U.S. PATENT DOCUMENTS

4,702,254 Zabara  
4,867,164 Zabara  
5,025,807 Zabara  
5,231,988 Wernicke  
5,299,569 Wernicke et al.  
5,540,734 Zabara  
5,540,730 Terry et al.  
5,700,282 Zabara  
5,707,400 Terry et al.

## Abstract:

A method is disclosed for treating nausea and vomiting by stimulation, comprising attaching one or more electrodes or wires on or under the skin of the neck, near the vagus nerve fibers in the neck; attaching these electrodes or wires to a current source; and stimulating the vagus nerve by means of this current source. The electrodes or wires can be directly attached to the current source by electrical wiring. Alternatively, they could remain under the skin or muscles of the neck with stimulation delivered from the current source to the electrodes and their associated electronics by means of induction. As a further alternative, they could be placed over the abdomen, or beneath the abdominal wall, in or near the gastrointestinal tract, or in or near the vagus nerve fibers in the vicinity of the stomach or esophagus. The current source can be adjusted with respect to milliamperes of current, duration of pulse, duration of pulse train, and frequency of pulse or pulse train repetition. Optionally, stimulation could be performed using a magnetic stimulator with the output pulse adjustable with respect to joules, duration of pulse, number of pulses, duration of pulse train, and frequency of pulse train. The device may be designed so that it would turn on manually. Alternatively, it may be designed so that it would turn on at designated times, turn off at designated times, or both. Provisions are made for the device to be connected to one or more sensors measuring gastric motility, heart rate, respiratory rate, skin resistance, brain activity, or other measures, with the pulses activated based on the activity measured by the sensors.

## Other Publications:

Abell TL, Riely CA. Hyperemesis gravidarum. *Gastroenterol.Clin.North Am.* 1992; 21: 835-849.  
Ben-Menachem E, Ristanovic R, Murphy J. Gestational outcomes in patients with epilepsy receiving vagus nerve stimulation. *Epilepsia* 1998; 39 (suppl 6): 180.  
Broussard CN, Richter JE. Nausea and vomiting of pregnancy. *Gastroenterol.Clin.North Am.* 1998a; 27: 123-151.  
Broussard CN, Richter JE. Treating gastro-oesophageal reflux disease during pregnancy and lactation: what are the safest therapy options? *Drug Saf* 1998b; 19: 325-337.  
Depue RH, Bernstein L, Ross RK, Judd HL, Henderson BE. Hyperemesis gravidarum in relation to estradiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study. *Am.J.Obstet.Gynecol.* 1987; 156: 1137-1141.  
Fairweather DV. Nausea and vomiting in pregnancy. *Am.J.Obstet.Gynecol.* 1968; 102: 135-175.  
Gadsby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. *Br.J.Gen.Pract.* 1993; 43: 245-248.  
Hod M, Orvieto R, Kaplan B, Friedman S, Ovadia J. Hyperemesis gravidarum. A review. *J.Reprod.Med.* 1994; 39: 605-612.

/

Jarnfelt-Samsioe A, Samsioe G, Velinder GM. Nausea and vomiting in pregnancy--a contribution to its epidemiology. *Gynecol.Obstet.Invest* 1983; 16: 221-229.

Kallen B. Hyperemesis during pregnancy and delivery outcome: a registry study. *Eur.J.Obstet.Gynecol.Reprod.Biol.* 1987; 26: 291-302.

Klebanoff MA, Koslowe PA, Kaslow R, Rhoads GG. Epidemiology of vomiting in early pregnancy. *Obstet.Gynecol.* 1985; 66: 612-616.

Nageotte MP, Briggs GG, Towers CV, Asrat T. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. *Am.J.Obstet.Gynecol.* 1996; 174: 1801-1805.

Parsonnet V, Myers GH, Holcomb WG, Zucker IR. Radio-frequency stimulation of the carotid baroreceptors in the treatment of hypertension. *Surg.Forum* 1966; 17:125-7.: 125-127.

Safari HR, Alsulyman OM, Gherman RB, Goodwin TM. Experience with oral methylprednisolone in the treatment of refractory hyperemesis gravidarum. *Am.J.Obstet.Gynecol.* 1998; 178: 1054-1058.

Schachter SC, Saper CB. Vagus Nerve Stimulation. *Epilepsia* 1998; 39: 677-686.

Snell LH, Haughey BP, Buck G, Marecki MA. Metabolic crisis: hyperemesis gravidarum. *J.Perinat.Neonatal Nurs.* 1998; 12: 26-37.

Zabara J. Neuroinhibition of xylazine induced emesis. *Pharmacol.Toxicol.* 1988; 63: 70-74.

Zabara J, Chaffee RB, Jr., Tansy MF. Neuroinhibition in the regulation of emesis. *Space Life Sci.* 1972; 3: 282-292.

Zabara JCRBJrTMF. Neuroinhibition in the Regulation of Emesis. *Space Life Sciences* 1972; 282-292.

#### Claims:

What is claimed is:

1. A method for treating nausea and vomiting comprising the steps of:

placing on, or attaching on or under the skin of the neck one or more electrodes;

attaching said electrodes to a current source, said current source powered by batteries or by standard commercial electrical current, and said current source adjustable with respect to milliamperes of current, duration of pulse, duration of pulse train, and frequency of pulse or pulse train repetition;

passing current from said current source to said electrodes;

whereby the vagus nerve in the neck can be stimulated, thereby reducing nausea and vomiting.

2. A method according to claim 1, whereby said electrodes are attached under the skin of the neck and current is delivered from said current source to said electrodes and their associated electronics by means of induction, rather than by direct attachment.

3. A method for treating nausea and vomiting by delivering a magnetic pulse from a magnetic stimulator, said stimulator adjustable with respect to joules, duration of pulse, number of pulses, duration of pulse train, and frequency of pulse or pulse train repetition;

whereby the vagus nerve in the neck can be stimulated, thereby reducing nausea and vomiting.

4. A method for treating nausea and vomiting comprising the steps of:

placing on, or attaching on or under the skin of the abdomen one or more electrodes, said means of stimulation selected from the group comprising electrodes or wires;

attaching said electrodes, said current source powered by batteries or by standard commercial electrode current, and said current source adjustable with respect to milliamperes of current, duration of pulse, duration of pulse train, and frequency of pulse or pulse train repetition;

passing current from said current source to said electrodes;

whereby the vagus nerve can be stimulated, thereby reducing nausea and vomiting.

5. A method for treating nausea and vomiting comprising the steps of:

attaching in the vicinity of an organ selected from the group comprising the stomach and esophagus one or more electrodes;

attaching said electrodes to a current source, said current source powered by batteries or by standard commercial electrode current, and said current source adjustable with respect to milliamperes of current, duration of pulse, duration of pulse train, and frequency of pulse or pulse train repetition;

passing current from said current source to said electrodes;

whereby the vagus nerve can be stimulated, thereby reducing nausea and vomiting.

6. A method according to claims 1-5 whereby stimulation is turned on manually.

7. A method according to claims 1-5 whereby stimulation is turned on automatically at predesignated times.

8. A method according to claims 1-5 whereby stimulation is turned off automatically at predesignated times.

9. A method according to claims 1-5 whereby stimulation is turned off automatically at predesignated times and off at predesignated times.

10. A method according to claims 1-5 whereby stimulation is turned on in response to one or more sensors, said sensors selected from the group comprising sensors measuring gastric motility, heart rate, respiratory rate, skin resistance, brain activity.

11. A method according to claims 1-10 in which the disorder treated is nausea or vomiting of pregnancy.

12. A method according to claims 1-10 in which the disorder treated is nausea or vomiting due to chemotherapy for cancer.

13. A method according to claims 1-10 in which the disorder treated is nausea or vomiting due to chemotherapy for inflammatory diseases of the body.

14. A method according to claims 1-10 in which the disorder treated is nausea or vomiting due to chemotherapy for connective tissue diseases of the body.

15. A method according to claims 1-10 in which the disorder treated is nausea or vomiting due to chemotherapy for inflammatory or autoimmune disorders of the peripheral or central nervous system

16. A method according to claims 1-10 in which the disorder treated is nausea or vomiting due to post-operative nausea.

18. A method according to claims 1-10 in which the disorder treated is nausea or vomiting due to motion sickness.

## BACKGROUND OF THE INVENTION

### 1. Field of the invention

The invention pertains to an acute method of treating nausea and vomiting, by means of stimulation of the vagus nerve.



## 2. Description of Related Art.

Nausea and vomiting is a significant problem during pregnancy, especially during early pregnancy. The problem is generally estimated to affect about 70-80% of women.[Parsonnet *et al.* 1966] [Broussard and Richter 1998a] [Gadsby *et al.* 1993] [Jarnfelt-Samsioe *et al.* 1983] [Klebanoff *et al.* 1985;Nageotte *et al.* 1996b] [Safari *et al.* 1998] [Snell *et al.* 1998]

This is especially a problem during early pregnancy, but can be present throughout pregnancy in about 20% of pregnant women.[Broussard and Richter 1998c] In a smaller number of pregnant women (about 0.3-2%0, this is severe enough to cause significant dehydration, disturbed electrolyte balance, weight loss, and ketosis, called hyperemesis gravidarum. ([Abell and Riely 1992] [Broussard and Richter 1998b;Depue *et al.* 1987] [Fairweather 1968] [Hod *et al.* 1994;Kallen 1987;Nageotte *et al.* 1996a] Admission to the hospital may be necessary.

Medications for emesis are available, but none are universally effective. Moreover, medications carry a risk of fetal malformations and their use is discouraged.[Broussard and Richter 1998d] Although, fluids, electrolytes and general nutrition can be replenished to the pregnant woman, nausea and vomiting cause considerable discomfort to the pregnant woman, and no ideal treatment is available. It is well known that the gastrointestinal tract is innervated by the vagus nerve [Schachter and Saper 1998;Zabara *et al.* 1972;Zabara 1988] and it has been shown that stimulation of vagal fibers can suppress experimental vomiting.[Zabara, Chaffee, Jr., and Tansy1972;Zabara1988] Therefore, stimulation of these fibers could be a means of treating nausea and vomiting of pregnancy.

This is not the only setting in which nausea and vomiting is a serious problem. Chemotherapy for cancer or for severe forms of connective tissue diseases or inflammatory diseases of the body, or chemotherapy for inflammatory or autoimmune disorders of the peripheral or central nervous system, can require use of agents that produce nausea, vomiting, or both. Examples of connective tissue diseases or inflammatory diseases of the body comprise disorders such as lupus erythematosus, rheumatoid arthritis, scleroderma, dermatomyositis, ulcerative colitis. Examples of inflammatory or autoimmune disorders of the peripheral nerves or central nervous system comprise disorders such as chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, neuosarcoidosis, central nervous system lupus, central nervous system vasculitis, monoclonal gammopathy. Finally, some patients experience severe motion sickness. Moreover, the disorders listed above can themselves cause nausea or vomiting. There are medications available for treating these situations. None of these are universally effective, however.

Bertolucci '91 (US Patent # 4,981,146) discloses treatment of nausea and vomiting by use of electrical stimulation of the wrist, in the region of the median nerve, at the P6 acupuncture point. This treatment has become commercially available with an FDA approved device (ReliefBand, <http://www.woodsidebiomedical.com>). This treatment has shown some benefit. However, as the company itself acknowledges on its web site ([http://www.woodsidebiomedical.com/scientific\\_evidence.asp](http://www.woodsidebiomedical.com/scientific_evidence.asp)) this treatment is not universally or completely effective. The efficacy found supports, however, the idea that stimulation could be an effective means of treating nausea and vomiting. The vagus nerve more directly connects to the central nervous system and is known to connect to centers pertinent to vomiting. Therefore, stimulation of the vagus nerve could more directly, and more effectively, treat nausea and vomiting.

Therefore, a need exists to improve the treatment of nausea and vomiting, a problem that affects a significant proportion of the population.

## SUMMARY OF THE INVENTION

An object of the invention provides for the use of vagal nerve stimulation for treating nausea and vomiting comprising the steps of:

- attaching on or under the skin of the neck one or more electrodes;
- attaching said electrodes to a current source, said current source powered by batteries or by standard commercial electrode current, and said current source adjustable with respect to milliamperes of current, duration of pulse, duration of pulse train, and frequency of pulse or pulse train repetition;



passing current from said current source to said electrodes;  
 whereby the vagus nerve in the neck can be stimulated, thereby reducing nausea and vomiting due to disorders selected from a list comprising pregnancy, chemotherapy for cancer, chemotherapy for inflammatory diseases of the body, chemotherapy for connective tissue diseases of the body, chemotherapy for inflammatory or autoimmune disorders of the peripheral or central nervous system, cancer, inflammatory or connective tissue disease, inflammatory disease of the body, inflammatory or autoimmune disorders of the peripheral or central nervous system, post-operative nausea, or motion sickness.

A further object of the invention provides for the use of vagal nerve stimulation for treating nausea and vomiting comprising the steps of:  
 attaching under the skin of the neck one or more electrodes;  
 utilizing a current source, said current source powered by batteries or by standard commercial electrode current, and said current source adjustable with respect to milliamperes of current, duration of pulse, duration of pulse train, and frequency of pulse or pulse train repetition;  
 passing current from said current source to said electrodes and their associated electronics by means of induction;  
 whereby the vagus nerve in the neck can be stimulated, thereby reducing nausea and vomiting due to disorders selected from a list comprising pregnancy, chemotherapy for cancer, chemotherapy for inflammatory diseases of the body, chemotherapy for connective tissue diseases of the body, chemotherapy for inflammatory or autoimmune disorders of the peripheral or central nervous system, cancer, inflammatory or connective tissue disease, inflammatory disease of the body, inflammatory or autoimmune disorders of the peripheral or central nervous system, post-operative nausea, or motion sickness.

A further object of the invention provides for the use of vagal nerve stimulation for treating nausea and vomiting by delivering a magnetic pulse from a magnetic stimulator, said stimulator adjustable with respect to joules, duration of pulse, number of pulses, duration of pulse train, and frequency of pulse or pulse train repetition;  
 whereby the vagus nerve in the neck can be stimulated, thereby reducing nausea and vomiting due to disorders selected from a list comprising pregnancy, chemotherapy for cancer, chemotherapy for inflammatory diseases of the body, chemotherapy for connective tissue diseases of the body, chemotherapy for inflammatory or autoimmune disorders of the peripheral or central nervous system, cancer, inflammatory or connective tissue disease, inflammatory disease of the body, inflammatory or autoimmune disorders of the peripheral or central nervous system, post-operative nausea, or motion sickness.

A further object of the invention provides for the use of vagal nerve stimulation for treating nausea and vomiting comprising the steps of:  
 attaching on or under the skin of the abdomen one or more electrodes;  
 attaching said electrodes to a current source, said current source powered by batteries or by standard commercial electrode current, and said current source adjustable with respect to milliamperes of current, duration of pulse, duration of pulse train, and frequency of pulse or pulse train repetition;  
 passing current from said current source to said electrodes;  
 whereby the vagus nerve in the neck can be stimulated, thereby reducing nausea and vomiting due to disorders selected from a list comprising pregnancy, chemotherapy for cancer, chemotherapy for inflammatory diseases of the body, chemotherapy for connective tissue diseases of the body, chemotherapy for inflammatory or autoimmune disorders of the peripheral or central nervous system, cancer, inflammatory or connective tissue disease, inflammatory disease of the body, inflammatory or autoimmune disorders of the peripheral or central nervous system, post-operative nausea, or motion sickness.

A further object of the invention provides for the use of vagal nerve stimulation for treating nausea and vomiting comprising the steps of:  
 attaching in the vicinity of an organ selected from the group comprising the stomach and esophagus one or more electrodes;  
 attaching said electrodes to a current source, said current source powered by batteries or by standard commercial electrode current, and said current source adjustable with respect to milliamperes of current, duration of pulse, duration of pulse train, and frequency of pulse or pulse train repetition;  
 passing current from said current source to the means of stimulation;

whereby the vagus nerve can be stimulated, thereby reducing nausea and vomiting due to disorders selected whereby the vagus nerve in the neck can be stimulated, thereby reducing nausea and vomiting due to disorders selected from a list comprising pregnancy, chemotherapy for cancer, chemotherapy for inflammatory diseases of the body, chemotherapy for connective tissue diseases of the body, chemotherapy for inflammatory or autoimmune disorders of the peripheral or central nervous system, cancer, inflammatory or connective tissue disease, inflammatory disease of the body, inflammatory or autoimmune disorders of the peripheral or central nervous system, post-operative nausea, or motion sickness.

The invention provides for the turning on stimulation either manually or automatically at predesignated times. The invention also provides a possibility for turning off stimulation automatically at predesignated times. The invention also provides for turning on stimulation in response to one or more sensors, said sensors selected from the group comprising sensors measuring gastric motility, heart rate, respiratory rate, skin resistance, brain activity.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the main components of the invention. Electrodes are placed on the skin or within the neck. A stimulation device is used to determine the stimulation parameters, which are then delivered through the electrodes.

#### DESCRIPTION OF PREFERRED EMBODIMENT

An embodiment of the invention relates to stimulation of the vagus nerve as a treatment for nausea and vomiting. The vagus nerve is a mixed nerve, and a primary function of this nerve is to innervate the heart, lungs, and gastrointestinal system. The right vagus nerve innervates the atria of the heart, the left the ventricles. The vagus nerve in the neck travels beneath the sternocleidomastoid muscle, and is about an inch below the skin surface. Fibers to the ventricles are less plentiful, so stimulation of the left vagus nerve is less likely to disrupt cardiac rhythm. Fibers from the left vagus nerve travel via the ventral surface of the esophagus, through the diaphragm, and then primarily to the anterior surface of the stomach.

Nausea and vomiting may be treated by stimulation of the vagus nerve. Stimulation could be performed as a single pulse, or as a train of pulses and the characteristics of the pulses including pulse amplitude (measured in amperes or joules), pulse duration, pulse train duration, and frequency of pulse or pulse train repetition. Stimulation could be accomplished by placing the stimulating electrodes directly on the neck, or by attaching electrodes to the neck. It is well known that electrodes can be attached easily in a number of ways. To give examples, each electrode could be attached to an adhesive substance, or the electrodes themselves could be attached with paste or collodion, or the electrodes could be in the shape of a needle and placed under the skin. In a preferred embodiment, the electrodes would be on the left side of the neck, over the vagus nerve, so as to stimulate the left vagus nerve.

Alternately, the electrodes could be placed under the skin, with no direct "wired" connection to the outside. These could be directly under the skin, or deeper, below the sternocleidomastoid muscle, so as to be closer to the vagus nerve. Stimulation would be delivered to the electrodes and their associated electronics by means of induction through the skin.

Alternately, stimulation electrodes could be held in place on the skin of the abdomen, or affixed by the adhesive means described above, or placed under the skin, or deeper, near the vagus nerve fibers that are in the vicinity of the stomach.

The electrodes could be in a variety of shapes including discs or wires, according to the invention. The current source either would be connected directly to the electrodes by means of wires or else current would be delivered through the skin to the electrodes and their associated electronics by means of induction. Electrodes could be reusable or disposable, according to the invention.

Alternatively, stimulation of the vagus nerve could be accomplished by magnetic stimulation. It is well known that magnetic stimulation can be focused, so that the effects of stimulation could be localized to a

specific region for which activation is desired. Since the nerve could be in a different location in different people, two- or three-dimensional imaging (i.e. magnetic resonance imaging or computerized tomography) could be used to precisely locate the target nerve region and localize this region with respect to specific locations on the skin surface.

The invention is envisioned as a means of controlling nausea and vomiting when it occurs, by stimulating the vagus nerve, thus reducing the nausea and vomiting. The effectiveness of vagus nerve stimulation for this purpose has been shown experimentally. [Zabara 1972; Zabara 1988] Direct vagus nerve stimulation is used clinically for treatment of intractable seizures of partial onset. (see Zabara '254, Zabara '164, Zabara '807) and this use is approved by the United States Food and Drug Administration (FDA) The approved device is placed surgically within the neck, in direct proximity to the nerve. Because of this, there is considerable experience regarding the possibility of adverse effects due to direct stimulation of the vagus nerve. This experience indicates that stimulation primarily causes effects localized to the area of stimulation. Common symptoms are hoarseness, throat pain, coughing, and dyspnea, paresthesias, and muscle pain, occurring at the time of stimulation. Importantly, there is no evidence to suggest that vagus nerve stimulation causes effects elsewhere in the body or causes birth defects. [Ben-Menachem *et al.* 1998]

Vagus nerve stimulation has been envisioned as a treatment for disorders other than epilepsy, including psychiatric disorders. Stimulation of other cranial nerves has been envisioned for treating a variety of neurological disorders including voluntary and involuntary disorders, migraine, epileptic seizure, motor disorders, Parkinson's disease, cerebral palsy, spasticity, chronic nervous illnesses and involuntary movement; pancreatic endocrine disorders including diabetes and hypoglycemia; dementia including cortical, subcortical, multi-infarct, Alzheimer's disease and Pick's disease; sleep disorders including central sleep apnea, insomnia and hypersomnia; eating disorders including anorexia nervosa, bulimia and compulsive overeating; and neuropsychiatric disorders including schizophrenia, depression and borderline personality disorder. (Zabara '569, Zabara '734)

Vagus nerve stimulation also has been envisioned for treating heart disorders (Zabara '282), hypertension (Terry '400, endocrine disorders such as diabetes and hypoglycemia (Wernicke '988). It also has been envisioned to treat gastric motility disorders such as duodenal ulcers, irritable colon, diverticulosis, and dumping syndrome. (Terry '730) Terry '730 however did not envision the use of vagus nerve stimulation for the innovative purposes envisioned in this disclosure.

Electrical stimulation is provided by two electrodes 1,2 placed on the vagus nerve. These are connected by a wire 3 to an implanted electronics package 4 that is also connected by a second wire 6 to an inductive pickup coil 6. The electronics package 4, wire 5, and pickup coil 6 are surgically placed in a convenient body cavity away from the patient's neck where the vagal nerve stimulation is delivered.

The electronics package derives its power from an external inductive loop transmitter 7 that is placed over the implanted pickup coil 6. All control information is also transmitted by this magnetic inductive link. The inductive loop transmitter 7 is connected by a cable 8 to the external stimulation electronics and power supply 9. The external stimulation electronics 9 delivers either periodic or continuous stimulation at the desired level either under program control or on demand by the patient pressing a button 10.

An alternative embodiment of the invention uses electrodes placed on the skin surface. Two electrodes 11, 12 deliver electrical stimulation and are connected by a cable 13 to the alternative external stimulator electronics 14. A patient push button 15 is also provided to allow for on demand stimulation, as well as programmed continuous or periodic stimulation.

Still another alternative embodiment envisions placing the electrodes on the skin of the abdomen or within the abdomen. Still another alternative embodiment envisions stimulation using a magnetic coil.

Still another alternative embodiment envisions using batteries within the device.

Still another alternative embodiment envisions powering the device using ordinary commercial alternating current.



Still another alternative embodiment envisions powering the device using magnetic stimulation.

While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to those of ordinary skill in the art that various changes and modifications can be made therein without departing from the spirit and scope of the invention.

The content of all books, journal articles, abstracts and the like cited herein are hereby incorporated herein by reference.

### Reference List

Abell TL, Riely CA. Hyperemesis gravidarum. *Gastroenterol.Clin.North Am.* 1992; 21: 835-849.

Ben-Menachem E, Ristanovic R, Murphy J. Gestational outcomes in patients with epilepsy receiving vagus nerve stimulation. *Epilepsia* 1998; 39 (suppl 6): 180.

Broussard CN, Richter JE. Nausea and vomiting of pregnancy. *Gastroenterol.Clin.North Am.* 1998c; 27: 123-151.

Broussard CN, Richter JE. Nausea and vomiting of pregnancy. *Gastroenterol.Clin.North Am.* 1998a; 27: 123-151.

Broussard CN, Richter JE. Nausea and vomiting of pregnancy. *Gastroenterol.Clin.North Am.* 1998b; 27: 123-151.

Broussard CN, Richter JE. Treating gastro-oesophageal reflux disease during pregnancy and lactation: what are the safest therapy options? *Drug Saf* 1998d; 19: 325-337.

Depue RH, Bernstein L, Ross RK, Judd HL, Henderson BE. Hyperemesis gravidarum in relation to estradiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study. *Am.J.Obstet.Gynecol.* 1987; 156: 1137-1141.

Fairweather DV. Nausea and vomiting in pregnancy. *Am.J.Obstet.Gynecol.* 1968; 102: 135-175.

Gadsby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. *Br.J.Gen.Pract.* 1993; 43: 245-248.

Hod M, Orvieto R, Kaplan B, Friedman S, Ovadia J. Hyperemesis gravidarum. A review. *J.Reprod.Med.* 1994; 39: 605-612.

Jarnfelt-Samsioe A, Samsioe G, Velinder GM. Nausea and vomiting in pregnancy--a contribution to its epidemiology. *Gynecol.Obstet.Invest* 1983; 16: 221-229.

Kallen B. Hyperemesis during pregnancy and delivery outcome: a registry study. Eur.J.Obstet.Gynecol.Reprod.Biol. 1987; 26: 291-302.

Klebanoff MA, Koslowe PA, Kaslow R, Rhoads GG. Epidemiology of vomiting in early pregnancy. Obstet.Gynecol. 1985; 66: 612-616.

Nageotte MP, Briggs GG, Towers CV, Asrat T. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. Am.J.Obstet.Gynecol. 1996a; 174: 1801-1805.

Nageotte MP, Briggs GG, Towers CV, Asrat T. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. Am.J.Obstet.Gynecol. 1996b; 174: 1801-1805.

Parsonnet V, Myers GH, Holcomb WG, Zucker IR. Radio-frequency stimulation of the carotid baroreceptors in the treatment of hypertension. Surg.Forum 1966; 17:125-7.: 125-127.

Safari HR, Alsulyman OM, Gherman RB, Goodwin TM. Experience with oral methylprednisolone in the treatment of refractory hyperemesis gravidarum. Am.J.Obstet.Gynecol. 1998; 178: 1054-1058.

Schachter SC, Saper CB. Vagus Nerve Stimulation. Epilepsia 1998; 39: 677-686.

Snell LH, Haughey BP, Buck G, Marecki MA. Metabolic crisis: hyperemesis gravidarum. J.Perinat.Neonatal Nurs. 1998; 12: 26-37.

Zabara J. Neuroinhibition of xylazine induced emesis. Pharmacol.Toxicol. 1988; 63: 70-74.

Zabara J, Chaffee RB, Jr., Tansy MF. Neuroinhibition in the regulation of emesis. Space Life Sci. 1972; 3: 282-292.

Zabara JCRBJrTMF. Neuroinhibition in the Regulation of Emesis. Space Life Sciences 1972; 282-292.

4247




Figure 1